(Boursier.com) — Poxel SA, a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces its participation in the 12th international meeting dedicated to AMPK (12th International Meeting on AMPK), on October 4.
Sophie Bozec, Executive Vice President, Pharmacology & Scientific Communication, will give a virtual presentation on the following topic: “Direct AMPK Activation: From Preclinical to Clinical. Perspectives in Rare Metabolic Diseases”.
This presentation will focus on PXL770, a molecule owned by Poxel, which is a first-in-class direct activator of adenosine monophosphate-activated protein kinase (AMPK) and whose development targets rare diseases, including adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD).
©2023 Boursier.com